Cannabidiol

New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder

Retrieved on: 
Friday, November 24, 2023

Partnering with the Soroka Medical Center and the National Autism Research Center, we are exploring new territory in ASD treatment.

Key Points: 
  • Partnering with the Soroka Medical Center and the National Autism Research Center, we are exploring new territory in ASD treatment.
  • We are driven by science and the goal of improving life quality for children with ASD and their families."
  • The spectrum of ASD is as diverse as the individuals it affects, challenging social interaction and communication.
  • SciSparc's bold initiative aims to offer a brighter, more connected future for those on the autism spectrum.

Aegis Sciences Corporation Announces Expanded Testing for Marijuana

Retrieved on: 
Tuesday, December 5, 2023

Aegis Sciences Corporation , a health care testing lab based in Nashville, Tenn., is pleased to announce it will be updating their urine testing for marijuana and other cannabinoids to include Delta‐8 Carboxy‐THC and Cannabidiol, in addition to Delta‐9 Carboxy‐THC.

Key Points: 
  • Aegis Sciences Corporation , a health care testing lab based in Nashville, Tenn., is pleased to announce it will be updating their urine testing for marijuana and other cannabinoids to include Delta‐8 Carboxy‐THC and Cannabidiol, in addition to Delta‐9 Carboxy‐THC.
  • The interpretation of marijuana results differs when considering presumptive vs definitive testing.
  • Aegis’s assay will continue to undergo presumptive testing by immunoassay with reflex to definitive testing by mass spectrometry.
  • “Expanding our marijuana assay to include other cannabinoids demonstrates our commitment to providing the most relevant testing available to healthcare providers,” said Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation.

Global CBD Consumer Health (Medical OTC Products, Nutraceuticals) Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023

The "CBD Consumer Health Market Size, Share & Trends Analysis Report By Product (Medical OTC Products, Nutraceuticals), By Distribution Channels (Retail Pharmacies, Retail Stores, Online), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CBD Consumer Health Market Size, Share & Trends Analysis Report By Product (Medical OTC Products, Nutraceuticals), By Distribution Channels (Retail Pharmacies, Retail Stores, Online), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global CBD consumer health market size is anticipated to reach USD 61.17 billion by 2030.
  • Based on product type, nutraceuticals dominated the market with a revenue share of 62.4% in 2019.
  • Based on distribution channels, retail pharmacies dominated the market for cannabidiol consumer health in 2019.

Rare Cannabinoid Company Launches THC + THCV Uplift Gummies - Unique Edibles With Dreamy Delta-9-THC, Energizing THCV To Combat The Munchies, and CBD Oil

Retrieved on: 
Thursday, December 7, 2023

HONOLULU, Dec. 7, 2023 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company is thrilled to announce the launch of their groundbreaking product, THC + THCV Uplift Gummies. This new addition to their product line combines the dreamy feel of Delta-9-THC with the energizing, appetite controlling effects of THCV, creating a one-of-a-kind experience for hemp and cannabis enthusiasts.

Key Points: 
  • HONOLULU, Dec. 7, 2023 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company is thrilled to announce the launch of their groundbreaking product, THC + THCV Uplift Gummies .
  • In fact, Rare Cannabinoid Company was the first to create a pure THCV oil tincture and THCV CBD oil in 2020, followed by the strongest THCV gummies on the market.
  • Like their THCV Gummies, Rare Cannabinoid Company's new THC + THCV Gummies boast an impressive 12.5mg of THCV per gummy, the largest amount available in any gummy on the market.
  • Other products with THCV or THC:
    THCV Gummies: For those seeking the energizing, appetite-controlling properties of THCV without any THC effects, Rare Cannabinoid Company also offers THCV gummies with Zero THC.

Wyld Introduces New Boysenberry Sleep Gummies

Retrieved on: 
Tuesday, November 14, 2023

CLACKAMAS, Ore., Nov. 14, 2023 /PRNewswire/ -- Wyld, one of the top five cannabis brands in the U.S., known for their best-selling cannabis infused edibles, is introducing a new sleep gummy, Boysenberry 1:1:1 THC:CBD:CBN Indica-enhanced, across the country.

Key Points: 
  • CLACKAMAS, Ore., Nov. 14, 2023 /PRNewswire/ -- Wyld, one of the top five cannabis brands in the U.S., known for their best-selling cannabis infused edibles, is introducing a new sleep gummy, Boysenberry 1:1:1 THC:CBD:CBN Indica-enhanced, across the country.
  • The boysenberry gummy is Wyld's first to include three cannabinoids – THC, CBD (cannabidiol), and CBN (cannabinol) – as well as botanical terpenes.
  • This addition to Wyld's sleep collection joins their Elderberry 2:1 THC:CBN gummy, which is the bestselling cannabis edible in the country according to BDSA data.
  • Wyld's Boysenberry Indica-enhanced gummies is available in the U.S.

Cannabis Testing Market to grow by USD 1.50 billion from 2022-2027 | Increasing global awareness about the benefits of cannabis drives the market growth - Technavio

Retrieved on: 
Wednesday, November 8, 2023

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The cannabis testing market size is expected to grow by USD 1.50 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The cannabis testing market size is expected to grow by USD 1.50 billion from 2022 to 2027.
  • Increasing global awareness about the benefits of cannabis drives the growth of the cannabis testing market.
  • Factors like advances in instruments in recent years have increased their adoption in the global cannabis testing market.
  • Growth of the cannabis testing market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of cannabis testing market vendors.

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

Retrieved on: 
Thursday, November 2, 2023

Another poster will present work on Artelo’s proprietary cocrystal of cannabidiol and tetramethylpyrazine, ART12.11, which has demonstrated improved efficacy and bioavailability compared to cannabidiol alone in a model of anxiety and depression.

Key Points: 
  • Another poster will present work on Artelo’s proprietary cocrystal of cannabidiol and tetramethylpyrazine, ART12.11, which has demonstrated improved efficacy and bioavailability compared to cannabidiol alone in a model of anxiety and depression.
  • “We are very pleased to have two of our programs being featured at this year’s conference,” commented Dr. Andrew Yates, Chief Scientific Officer at Artelo Biosciences.
  • ART26.12 has demonstrated a positive effect in numerous animal models of painful neuropathies, including chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy.
  • For more information about the conference, please visit Neuroscience 2023 .

How can I get some sleep? Which treatments actually work?

Retrieved on: 
Thursday, October 26, 2023

This article is the next in The Conversation’s six-part series on insomnia, which charts the rise of insomnia during industrialisation to sleep apps today.

Key Points: 
  • This article is the next in The Conversation’s six-part series on insomnia, which charts the rise of insomnia during industrialisation to sleep apps today.
  • Do these sleep problems make you feel fatigued, strung-out, or exhausted during the day?
  • Read more:
    A short history of insomnia and how we became obsessed with sleep

What not to do


These probably won’t help:
spending more time in bed often results in more time spent awake in bed, which can make insomnia patterns worse
drinking coffee and taking naps might help get you through the day. But caffeine stays in the system for many hours, and can disrupt our sleep if you drink too much of it, especially after about 2pm. If naps last for more than 30 minutes, or occur after about 4pm, this can reduce your “sleep debt”, and can make it more difficult to fall asleep in the evening
drinking alcohol might help you fall asleep quicker, but can cause more frequent awakenings, change how long you sleep, change the time spent in different “stages” of sleep, and reduce the overall quality of sleep. Therefore, it is not recommended as a sleep aid.

Read more:
Why do I fall asleep on the sofa but am wide awake when I get to bed?

What to do next?

  • So, the next stage is a type of non-drug therapy known as cognitive behavioural therapy for insomnia (or CBTi for short).
  • It involves education about sleep, and offers psychological and behavioural treatments that address the underlying causes of long-term insomnia.
  • Some GPs are trained to offer CBTi, but it’s more usual for specialist sleep psychologists to offer it.
  • But many psychologists will also charge a gap fee above the Medicare subsidy, making access to CBTi a challenge for some.

What if that doesn’t work?

  • Some lifestyle and work factors, such as shift-work, might also require management by a specialist sleep doctor.
  • Read more:
    Counting the wrong sheep: why trouble sleeping is about more than just individual lifestyles and habits

What about sleeping pills?

  • Sleeping pills are not the recommended first-line way to manage insomnia.
  • Read more:
    Some reasons why you should avoid sleeping pills

Are there new treatments? How about medicinal cannabis?


Two newer drugs, known as “orexin receptor antagonists”, are available in Australia (suvorexant and lemborexant). These block the wake-promoting pathways in the brain. Early data suggests they are effective in improving sleep, and have lower risk of potential side-effects, tolerance and dependence compared with earlier medicines. However, we don’t know if they work or are safe over the long term.

  • Medicinal cannabis has only in recent years been studied as a treatment for insomnia.
  • In an Australian survey, more than half of people using medicinal cannabis said they used it to treat insomnia.

What now?

  • Your GP can help identify and manage these.
  • Your GP can also help you access other treatments if your insomnia is more long term.
  • Dr Sweetman reports previous research funding and/or consultancy work for; the National Health and Medical Research Council, The Hospital Research Foundation, Flinders University, Flinders Foundation, ResMed, Philips, Cerebra, Re-Time, and Australian Doctor.
  • Nicole Grivell is involved in the Australasian Sleep Association as a co-chair of the Primary Care Council and as a member of the Conference Committee.
  • She has previously received PhD funding from the Flinders Foundation in the form of a Nick Antic Sleep Research PhD Scholarship.

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

Retrieved on: 
Thursday, October 19, 2023

IGC Pharma, Inc. (“IGC,” “IGC Pharma” or the “Company”) (NYSE American: IGC), a visionary clinical-stage pharmaceutical company, is thrilled to announce a significant milestone: the grant of European Patent No.

Key Points: 
  • IGC Pharma, Inc. (“IGC,” “IGC Pharma” or the “Company”) (NYSE American: IGC), a visionary clinical-stage pharmaceutical company, is thrilled to announce a significant milestone: the grant of European Patent No.
  • 3193862 by the European Patent Office (“EPO”) for our innovative "Cannabinoid Composition and Method for Treating Pain."
  • IGC Pharma is at the forefront of innovation, dedicated to enhancing the quality of life and well-being of those in pain.
  • Ram Mukunda, CEO of IGC Pharma, commented, “IGC Pharma is committed to advancing pain relief therapies rooted in decades of rigorous scientific research.

Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and global CBD research

Retrieved on: 
Monday, October 23, 2023

Research over the past several months has identified animals that metabolize cannabidiol (CBD), administered as a liposomal CBD injection, in a manner similar to humans.

Key Points: 
  • Research over the past several months has identified animals that metabolize cannabidiol (CBD), administered as a liposomal CBD injection, in a manner similar to humans.
  • This groundbreaking discovery, is not unique to our LPT-CBD and can be implemented on these animals using other Cannabidiol (CBD) delivery methods", said Iris Bincovich, CEO of Innocan Pharma.
  • This practical application of our liposomal CBD formulation highlights its potential to revolutionize healthcare for animals as well as humans.
  • Our groundbreaking data identified animals that have the potential for studying pharmacokinetics, pharmacodynamics, and safety of liposomal-CBD formulation.